ArticleOman journal of ophthalmology
Serum vascular endothelial growth factor in patients with nonmelanoma primary ocular malignancies: A possible potential biomarker of tumor progression and poor prognosis.
Article in Oman journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextVascular endothelial growth factor (VEGF) is a potent and specific angiogenic growth factor that may participate in the formation of the vascular tumor stroma. Pretreatment VEGF levels can be a biomarker to predict tumor progression and prognosis in patients with primary ocular malignancies.
aimsThe aim of this study was to estimate the serum vascular endothelial growth factor (VEGF) in various ocular malignancies, correlate with clinicpathological parameters, and assess its prognostic and therapeutic implications. SETTINGS AND
designThis hospital-based observational study includes a total of 32 newly diagnosed histopathologically confirmed, patients with ocular malignancy. SUBJECTS AND
methodsCirculating VEGF levels were measured using as and which enzyme-linked immunosorbent assay technique in 32 patients and 16 healthy controls. Serum VEGF levels were expressed as means ± standard deviation and compared using a one-way analysis of variance test, Chi-squared test, and Student's
resultsMean serum VEGF levels were significantly raised in patients as compared to healthy controls (79.85 ± 22.16 vs 67.15 ± 6.84 pg/ml). Moreover, VEGF levels were maximum in retinoblastoma (111.86 ± 33.54 pg/ml), followed by sebaceous gland carcinoma (77.83 ± 11.37 pg/ml), ocular surface squamous neoplasia (70.57 ± 5.84 pg/ml), and basal cell carcinoma (67.96 ± 4.55 pg/ml). No significant change in serum VEGF level depending on histopathological differentiation (
conclusionsSerum VEGF may be a useful biomarker to assess disease severity, predict prognosis, and assess the likelihood of recurrence in various ocular cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.